top of page

AMR

Patient Alliance

It's Time to Face the Facts

AMR-Logo-Blank.png

Failure to Act Is an Act of Failure

GET INVOLVED

Read and sign our statement on Antimicrobial resistance by following the link bellow

DISCOVER

Visit our repository of materials on Antimicrobial resistance by following the link bellow

ABOUT US

Dr Neda Milevska Kostova

Chair a.i.

Board Chair at International Alliance of Patients' Organisations

President of the IAPO Patients for Patient Safety Observatory

Christine Verini

Chief Operating Officer at CancerCare

Danjuma Adda

President of World Hepatitis Alliance

Public health expert

Mariano Votta

Vice-chair a.i.

Responsible for EU Affairs at Cittadinanzattiva

Director at Active Citizenship Network (ACN)

Thomas N. Heymann

President and CEO of Sepsis Alliance

Advisory board member of the Canadian Sepsis Foundation

Daniel Gallego

President of European Kidney Patients Federation

President of the National Federation of Associations for the Fight Against Kidney Diseases (ALCER)

Speakers

REGIONAL CHAPTERS

AMR_AFRO-2.png
AMR_SEA-2.png

PARTNERS

IAPO-logo.jpg
ACN-cittadinanzattiva-logo.gif
logo-IAPO-P4PSO.png
ALCER-logo-vertical.jpg
Sepsis-Alliance.jpg
HIGH RES EKPF LOGO.jpg
CANCER-CARE_New 75 Logo_Blue.jpg
Our misson

OUR MISSION

What is  our mission?

Our mission is to advocate for the needs and rights of patients in the fight against AMR, to increase awareness about the issue of AMR and to promote policies that ensure access to appropriate antimicrobial treatments for patients.

How do we work?

We collaborate with other stakeholders, including healthcare professionals, policymakers, and concerned industries, to promote a collaborative and coordinated approach towards AMR known as One Health.

What have we done so far?

We have created a patient-centred consensus on AMR that outlines key principles and recommendations for addressing the issue from a patient perspective. Our consensus emphasises the need for increased patient education, improved disease prevention and control measures, appropriate use of antimicrobial treatments, and increased funding and research for the development of new treatments.

Updates
bottom of page